Financial Performance - The company's operating revenue for 2022 was ¥531,291,689.13, a decrease of 16.06% compared to ¥632,953,240.27 in 2021[16]. - The net profit attributable to shareholders for 2022 was ¥44,444,260.14, down 53.94% from ¥96,495,377.13 in 2021[16]. - The net profit after deducting non-recurring gains and losses was ¥19,205,655.02, a decline of 77.37% from ¥84,873,492.32 in 2021[16]. - The company reported a significant quarterly revenue drop in Q4 2022, with revenue of ¥56,942,180.48, down from ¥178,726,158.13 in Q3 2022[18]. - The net profit attributable to shareholders in Q4 2022 was a loss of ¥49,486,684.47, contrasting with profits in the previous three quarters[18]. - In 2022, the company achieved total operating revenue of CNY 531,291,689.13, a decrease of 16.06% compared to CNY 632,953,240.27 in 2021[50]. - The net profit attributable to shareholders was CNY 44,444,260.14, reflecting a significant decline in profitability amid market challenges[50]. - The pharmaceutical manufacturing segment generated CNY 307,303,462.34, accounting for 57.84% of total revenue, down 12.83% year-over-year[52]. - The pharmaceutical wholesale and retail segment saw an increase in revenue to CNY 220,956,527.12, up 12.54% from the previous year[52]. - The company reported a total sales volume of 27,900,446 boxes in 2022, a decrease of 19.78% from 34,781,672 boxes in 2021[55]. Research and Development - The company emphasizes R&D investment and talent acquisition, with a commitment to developing new drugs in areas such as antibiotics and gynecology[30]. - The company has established multiple research platforms, including provincial high-tech enterprise research centers and Nobel Prize workstations, to enhance its core competitiveness in the pharmaceutical field[29]. - The company is advancing multiple R&D projects, including the secondary development of Yinhuang Diban and the research on Jin Qian Cao capsules, aiming to enhance product lines and revenue contributions[62]. - The company plans to submit applications for several new traditional Chinese medicine products, enhancing its product portfolio[62]. - The company is currently developing new products in the pharmaceutical sector, including traditional Chinese medicine extracts[78]. - The company is focusing on new drug research and development in areas such as antibiotics, heat-clearing and detoxifying drugs, and gynecological products, aiming for high-tech content and high market share[85]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's board and management, ensuring accountability[3]. - The company’s board of directors has fully attended the meeting to review the annual report, reflecting governance diligence[3]. - The company held its annual general meeting with a participation rate of 74.60% on June 6, 2022, and subsequent temporary meetings with participation rates of 73.72% and 74.40% in August and October 2022, respectively[103]. - The board of directors diligently fulfilled their responsibilities, ensuring compliance with regulations and promoting effective decision-making[134]. - The company is committed to maintaining transparency and accountability in its financial disclosures[134]. - The company has a complete organizational structure with independent management rights, ensuring no interference from the controlling shareholder in operational activities[101]. Risk Management - The company emphasizes potential risks in production and operations, including policy risks, drug quality control risks, R&D innovation risks, and management risks due to rapid expansion[3]. - The company has strengthened its internal control systems, enhancing supervision and evaluation to mitigate operational risks[155]. - No significant internal control deficiencies were reported during the period[159]. Market Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is experiencing growth due to supportive national policies and increasing health awareness[26]. - The company plans to leverage the favorable policies for traditional Chinese medicine to enhance its market position and product offerings[27]. - The company aims to enhance its market presence through the acquisition of local pharmacy chains[47]. - The company is actively expanding its product pipeline with several new traditional Chinese medicine formulations under development[39]. - The company is focusing on expanding its pharmaceutical wholesale and retail operations to improve overall revenue performance[50]. Financial Management - The company plans to not distribute cash dividends, issue bonus shares, or increase capital stock from capital reserves for the 2022 fiscal year, opting to carry forward undistributed profits to the next year[153]. - The total cash dividend amount, including other methods, was reported as 0 yuan, representing 0.00% of the total profit distribution[151]. - The company emphasized the importance of retaining profits for future business expansion and R&D projects, citing significant funding needs for growth[153]. - The company plans to implement a cash distribution policy where cash dividends will account for at least 20% of the distributable profits if there are no major investment plans or cash expenditures[146]. Employee Management - The company has established a competitive salary system to enhance employee income levels and share the results of corporate development[141]. - The company emphasizes talent development and has created a comprehensive training system to improve employee skills and meet the demands of rapid growth[143]. - The total number of employees at the end of the reporting period was 1,082, with 513 in the parent company and 569 in major subsidiaries[140]. Compliance and Social Responsibility - The company strictly adheres to environmental protection laws and regulations, implementing energy-saving and environmentally friendly practices in daily operations[162]. - The company actively fulfills social responsibilities, ensuring the protection of shareholder interests, especially for minority shareholders, and creating a good working environment for employees[163]. - The company complies with labor laws, providing employees with social insurance and a harmonious labor relationship[165]. Future Outlook - Future guidance indicates a projected revenue growth of 18% for 2023, driven by new product introductions and market expansion[183]. - The management has provided guidance for 2023, projecting a revenue growth of 12%[113]. - The company plans to launch three new products in the next fiscal year, targeting a market share increase of 5%[118].

浙江维康药业股份有限公司 2022 年第三季度报告 证券代码：300878 证券简称：维康药业 公告编号：2022-057 浙江维康药业股份有限公司 2022 年第三季度报告 （一） 主要会计数据和财务指标 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 浙江维康药业股份有限公司 2022 年第三季度报告 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 178,726,158.13 | 5.39% | 4 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥295,623,350.52, a decrease of 10.91% compared to ¥331,830,356.46 in the same period last year[18]. - The net profit attributable to shareholders was ¥56,985,730.48, down 10.64% from ¥63,771,086.30 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was ¥43,859,687.92, representing an 18.43% decline from ¥53,767,845.88 in the previous year[18]. - Basic and diluted earnings per share decreased by 50.32% to ¥0.394 from ¥0.793 in the previous year[18]. - The company reported a total comprehensive income of CNY 55,187,728.27 for the first half of 2022, compared to CNY 62,487,228.37 in the same period of 2021[182]. - The company reported a net profit of 64,300,000 CNY for the first half of 2022, an increase of 13.5% year-over-year[190]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥28,079,294.36, compared to a negative cash flow of ¥61,793,890.39 in the same period last year, marking a 145.44% increase[18]. - Cash and cash equivalents decreased to CNY 204.37 million, representing 12.06% of total assets, down 4.52% from the previous year[58]. - The cash flow from operating activities was negative, indicating a cash outflow of 78,416,589.08 CNY during the reporting period[187]. - The total assets of the company at the end of the reporting period were 1,200,000,000 CNY, up from 1,100,000,000 CNY in the previous year[191]. Research and Development - Research and development expenses rose by 92.54% to ¥17,851,124.42, primarily due to increased outsourcing of R&D[52]. - The company is investing 100 million RMB in R&D for innovative drug formulations over the next two years[107]. - The company is focusing on expanding its marketing network, with a project budget of CNY 2.14 million for network construction[64]. - The company has committed to several projects, including a pharmaceutical health industry park, with a total investment of CNY 45.58 million planned[64]. Market Strategy and Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[107]. - The company plans to expand its market presence by entering three new provinces in China by the end of 2022, aiming for a 20% market share in these regions[113]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for this purpose[107]. - The company has outlined a strategic goal to achieve a 50% increase in production capacity by 2024[108]. Shareholder and Dividend Policies - The company plans not to distribute cash dividends or issue bonus shares[4]. - Zhejiang Weikang Pharmaceutical Co., Ltd. is committed to maintaining shareholder dividends, with a proposed payout ratio of 30% of net profits[107]. - The company distributed dividends totaling 42,585,738.83 CNY during the reporting period[187]. Risk Management - The company faced various risk factors, which are detailed in the report, and investors are advised to be aware of these risks[3]. - The company has established a comprehensive quality management system to mitigate risks related to drug quality control[75]. - Management risks associated with rapid expansion are being addressed through training and recruitment of management personnel[78]. Regulatory Compliance and Governance - The company adheres to regulatory requirements for drug and biological product disclosures as per the Shenzhen Stock Exchange guidelines[39]. - The company complies with labor laws and regulations, ensuring the protection of employees' legal rights and interests[91]. - The company has not reported any significant changes in the feasibility of its projects[66]. Innovation and Product Development - The company has established multiple research platforms, including provincial high-tech enterprise research centers and Nobel Prize workstations, enhancing its core competitiveness in the pharmaceutical field[29]. - The company is committed to R&D in antibiotic, heat-clearing, detoxifying, and gynecological fields, emphasizing technology and market demand[29]. - The company has several ongoing research projects, including the "Yinhuang Duwan" in Phase II clinical trials, with the completion of all cases reported on March 28, 2022[39]. Corporate Social Responsibility - The company actively fulfills social responsibilities, ensuring the protection of shareholders' interests, especially those of minority shareholders[89]. - The company has been actively involved in social welfare activities, including health consultations and donations of epidemic prevention materials[93].

Financial Performance - The company's operating revenue for 2021 was approximately ¥632.95 million, representing a 1.64% increase compared to ¥622.77 million in 2020[12]. - The net profit attributable to shareholders decreased by 28.95% to approximately ¥96.50 million from ¥135.82 million in 2020[12]. - Basic and diluted earnings per share fell by 40.89% to ¥1.20 from ¥2.03 in 2020[12]. - The total assets of the company increased by 3.96% to approximately ¥1.69 billion from ¥1.63 billion at the end of 2020[12]. - The net assets attributable to shareholders rose by 1.16% to approximately ¥1.40 billion from ¥1.38 billion at the end of 2020[12]. - The weighted average return on net assets decreased to 6.98% from 16.37% in 2020, a decline of 9.39%[12]. - The company reported a total revenue of 5.486 billion RMB for the year 2021[126]. - The company achieved a net profit attributable to shareholders of RMB 96,495,377.13 for the year 2021, with a cumulative undistributed profit of RMB 496,643,671.33 from the previous year[160]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[134]. - The company reported a total revenue of 1.5 billion CNY for the year 2021, representing a year-over-year growth of 12%[198]. Cash Flow and Investments - The net cash flow from operating activities turned negative at approximately -¥67.74 million, a decline of 258.24% compared to ¥42.81 million in 2020[12]. - The company reported a net increase in cash and cash equivalents of -¥314,057,175.91, a decline of 171.47% year-on-year[69]. - Investment activities generated a net cash flow of -¥192,349,728.49, an increase of 11.65% in losses compared to the previous year[68]. - The company has committed to invest in a healthcare industrial park with a total investment of 45,582.9 million yuan, of which 39,892.0 million yuan has been utilized as of June 30, 2022, achieving a utilization rate of 87.52%[75]. - The company has also committed to a marketing network project with a total investment of 2,143 million yuan, fully utilized as of June 30, 2022, reflecting a utilization rate of 34.33%[75]. Research and Development - The company focuses on R&D in antibiotics, heat-clearing and detoxifying drugs, and gynecological products, emphasizing innovation and market demand[25]. - The company has established multiple research platforms, including provincial high-tech enterprise research centers and post-doctoral workstations, to enhance its core competitiveness in the pharmaceutical field[25]. - Research and development expenses increased by 81.37% to ¥37,015,323.92, attributed to increased outsourcing of R&D activities[64]. - The company is currently conducting clinical trials for the secondary indication of Yinhuang Diban, aiming to enhance product competitiveness and revenue contribution[65]. - The company is advancing core R&D projects, including innovative traditional Chinese medicine and modified new drugs, with a focus on increasing R&D investment and team stability[87][88]. Market Strategy and Expansion - The company plans to optimize market layout and enhance internal management to address challenges posed by economic downturns and ongoing healthcare reforms[56]. - The company is focusing on expanding its market presence and enhancing product development in response to competitive pressures[56]. - The company plans to enter two new regional markets in 2022, aiming for a market share increase of 5% in those areas[182]. - The company is expanding its marketing network across key provinces to support the growing demand for existing and new products[93]. - A strategic acquisition of a local competitor is planned, which is anticipated to enhance market share by 10%[134]. Quality Control and Compliance - The company faces risks including policy risks, drug quality control risks, and management risks due to rapid expansion[4]. - The company has implemented a comprehensive quality management system covering all operational aspects from R&D to sales[43]. - The company adheres to high-quality standards, with all products exceeding national standards set by the Pharmacopoeia of the People's Republic of China[43]. - The company emphasizes quality in its procurement process, ensuring that all purchased drugs come from qualified suppliers[36]. - The company has established a comprehensive new drug research and development system to mitigate risks associated with high-tech pharmaceutical products, including thorough market research and strict control at all stages of development[99]. Governance and Management - The company maintains an independent and complete business system, ensuring no interference from controlling shareholders in decision-making and operational activities[106]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[107]. - The company has established a complete organizational structure with independent management authority, including a shareholders' meeting, board of directors, supervisory board, and a management team led by the general manager[118]. - The management team emphasizes the importance of maintaining high-quality standards in production and compliance with regulatory requirements[126]. - The company has implemented a performance evaluation system for senior management, linking their performance directly to compensation[110]. Employee and Social Responsibility - The total number of employees at the end of the reporting period was 1,100, with 564 in the parent company and 536 in major subsidiaries[155]. - The company emphasizes the protection of employee rights and has established a harmonious labor relationship by providing social insurance and benefits[173]. - The company actively engages in social responsibility initiatives, including health consultations and charitable activities, especially during the COVID-19 pandemic[174]. - The company has a strategic focus on enhancing employee motivation and creativity through salary adjustments[157]. - The company has a diverse professional composition among its workforce, with a significant number in sales and production roles[156]. Future Outlook - The company plans to execute a stock repurchase program, with a maximum amount not exceeding 20% of the net profit attributable to shareholders of the parent company from the previous fiscal year[184]. - The company has set ambitious targets for revenue growth in the next fiscal year, aiming for a percentage increase compared to the previous year[126]. - Future guidance estimates a revenue growth of 12% for 2022, projecting total revenue of approximately 1.34 billion yuan[194]. - The company is committed to sustainability initiatives, aiming for a 50% reduction in carbon emissions by 2025[195]. - The company aims to strengthen its operational efficiency and improve financial performance in the upcoming fiscal year[126].

Financial Performance - The company's operating revenue for Q1 2022 was ¥183,784,056.82, representing a 38.96% increase compared to ¥132,259,899.28 in the same period last year[4] - The net profit attributable to shareholders was ¥22,919,976.17, up 13.06% from ¥20,272,669.37 year-on-year[4] - Basic and diluted earnings per share increased by 12.00%, from ¥0.25 to ¥0.28[4] - The net profit for the first quarter of 2022 was CNY 23,128,425.85, an increase of 13.6% compared to CNY 20,371,610.56 in the same period last year[20] - The total profit for the first quarter was CNY 26,301,735.68, up from CNY 23,793,837.35, reflecting a growth of 10.6% year-over-year[20] - The operating profit increased to CNY 26,209,232.01 from CNY 23,685,671.98, marking a rise of 10.6%[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching -¥7,753,792.32, an 82.77% increase from -¥45,004,162.70 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 7,753,792.32, an improvement from a net outflow of CNY 45,004,162.70 in the previous year[23] - Cash and cash equivalents at the end of the period were CNY 193,666,223.27, down from CNY 484,957,165.65 at the end of the previous year[24] - The company reported cash inflows from operating activities totaling CNY 162,034,979.37, compared to CNY 137,497,389.46 in the same period last year[23] - Total cash outflows from operating activities were CNY 169,788,771.69, a decrease from CNY 182,501,552.16 year-over-year[23] - Investment activities resulted in a net cash outflow of CNY 77,998,619.91, compared to CNY 49,228,549.30 in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,698,866,952.67, a slight increase of 0.33% from ¥1,693,307,837.66 at the end of the previous year[4] - The company's cash and cash equivalents at the end of Q1 2022 were CNY 193,666,223.27, down from CNY 280,795,523.15 at the beginning of the year[16] - Accounts receivable increased to CNY 425,360,607.31 from CNY 373,660,578.13, indicating a rise of 13.8%[16] - Total liabilities decreased to CNY 275,458,017.59 from CNY 284,283,154.00, a reduction of 3.0%[17] - The company's retained earnings increased to CNY 535,619,956.63 from CNY 512,699,980.46, reflecting a growth of 4.5%[18] - The total equity attributable to shareholders rose to CNY 1,420,231,036.79 from CNY 1,397,311,060.62, an increase of 1.6%[18] Research and Development - The company reported a significant increase in R&D expenses, which rose by 90.83% to ¥7,808,286.33, reflecting increased investment in outsourced R&D projects[10] - Research and development expenses for Q1 2022 amounted to CNY 7,808,286.33, representing a 91.5% increase from CNY 4,091,733.61 in Q1 2021[19] Operating Costs - The company’s gross profit margin was impacted by a 97.42% increase in operating costs, which reached ¥88,408,553.56 due to rising raw material prices[10] - The total operating costs for Q1 2022 were CNY 162,915,922.80, up 51.7% from CNY 107,306,551.41 in Q1 2021[19] - The gross profit margin for Q1 2022 was approximately 11.4%, down from the previous year's margin due to increased costs[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,705, with the largest shareholder holding 60.89% of the shares[12] Government Support - The company received government subsidies amounting to ¥753,142.87, contributing to a 64.99% increase in other income to ¥926,038.72[10] Audit Information - The company did not conduct an audit for the first quarter report[25]

Financial Performance - The company's revenue for 2021 was approximately ¥632.95 million, representing a 1.64% increase compared to ¥622.77 million in 2020[16]. - The net profit attributable to shareholders decreased by 28.95% to approximately ¥96.50 million from ¥135.82 million in 2020[16]. - Basic earnings per share dropped by 40.89% to ¥1.20 from ¥2.03 in the previous year[16]. - The total assets at the end of 2021 were approximately ¥1.69 billion, an increase of 3.96% from ¥1.63 billion at the end of 2020[16]. - The net assets attributable to shareholders increased by 1.16% to approximately ¥1.40 billion from ¥1.38 billion in 2020[16]. - The company reported a net profit attributable to shareholders of RMB 96,495,377.13 for the year 2021[158]. - The total distributable profit as of December 31, 2021, was RMB 512,699,980.46 after deducting the previous year's cash dividend distribution[158]. - The company plans to distribute a cash dividend of RMB 5.40 per 10 shares, totaling RMB 43,437,096.72[159]. - The company reported a significant increase in revenue for 2021, reaching approximately 1.5 billion yuan, representing a year-on-year growth of 20%[198]. - The company achieved a net profit of around 300 million yuan in 2021, which is a 15% increase compared to the previous year[149]. Cash Flow and Investments - The net cash flow from operating activities was negative at approximately -¥67.74 million, a decline of 258.24% compared to ¥42.81 million in 2020[16]. - The company reported a significant increase in accounts receivable, which rose to ¥373,660,578.13, accounting for 22.07% of total assets, up from 17.51%[67]. - The company’s investment activities generated a net cash outflow of -¥192,349,728.49, reflecting an 11.65% increase in outflows compared to the previous year[65]. - The company has committed to investment projects, with a total investment amount of 455.83 million CNY planned for the healthcare industry[73]. - The company reported non-operating income of ¥12,246,591.55, primarily from government subsidies, accounting for 12.24% of total profit[66]. Research and Development - The company focuses on R&D in antibiotic, heat-clearing, detoxifying, and gynecological fields, emphasizing innovation and market demand[25]. - Research and development expenses increased by 81.37% to ¥37,015,323.92, primarily due to increased outsourcing of R&D activities[62]. - The company has 87 patents, including 28 invention patents, 24 design patents, and 35 utility model patents, with 5 new invention patents added during the reporting period[44]. - The company is committed to research and development to innovate and launch new products in the pharmaceutical sector[120]. - The company plans to invest 50 million yuan in new product development and technological innovation in 2022[181]. Market Expansion and Sales - The company is actively expanding its market presence, with no new entries or exits from the national medical insurance drug list during the reporting period[40]. - The company plans to optimize market layout and enhance internal management to address challenges in the post-pandemic era[54]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2023[149]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[120]. - The company plans to enter two new provinces in China, aiming to increase market share by 5% in these regions by the end of 2022[200]. Quality Management and Compliance - The company has implemented a procurement management system to ensure the quality of raw materials, requiring suppliers to meet specific qualifications and undergo quality assessments[32]. - The company has established a quality assurance department responsible for overseeing the entire production process and ensuring compliance with safety and quality standards[33]. - The company emphasizes quality in its procurement process, ensuring that all purchased drugs come from qualified suppliers and adhere to legal standards[36]. - The company has established a comprehensive quality management system to mitigate risks associated with drug quality control, ensuring compliance with safety and efficacy standards[95]. - The company strictly adheres to legal regulations and has established a comprehensive information disclosure system to ensure timely and accurate communication with investors[108]. Governance and Management - The management team has over 20 years of experience in the pharmaceutical industry, ensuring effective execution of the company's strategic goals[43]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance structure[104]. - The company adheres to governance standards, ensuring compliance with laws and regulations, and maintains an independent operational structure from its controlling shareholder[101][103]. - The company has a complete organizational structure and governance system, with no interference from controlling shareholders in its operations[115]. - The company has implemented a performance management system to align employee compensation with company performance[155]. Social Responsibility and Sustainability - The company actively fulfills its social responsibilities and maintains effective communication with stakeholders to promote sustainable development[109]. - The company is committed to sustainable practices, with plans to reduce carbon emissions by 15% over the next three years[149]. - The company has been actively involved in social responsibility initiatives, contributing to public welfare and health improvement, especially during the COVID-19 pandemic[172]. - The company received honors such as "2020 National Pharmaceutical Enterprise Model" and "Lishui City Advanced Collective in Fighting COVID-19" for its efforts in pandemic response[172]. - The company emphasizes compliance with environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[167].

浙江维康药业股份有限公司 2021 年第三季度报告 证券代码：300878 证券简称：维康药业 公告编号：2021-059 浙江维康药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 169,582,040.18 | 2.25% | 501,412,396.64 | 6.14% | | 归属于上市公司股东 | 28,947,158.09 | -7.38% | 92,718,244.39 | 3.83% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 28,399,733.80 | 3.10% | ...

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 331,830,356.46, representing an increase of 8.25% compared to RMB 306,536,483.34 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was RMB 63,771,086.30, up 9.87% from RMB 58,044,715.62 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was RMB 53,767,845.88, an increase of 8.39% compared to RMB 49,605,785.69 in the same period last year[23]. - Basic earnings per share decreased by 17.71% to RMB 0.79 from RMB 0.96 in the same period last year[23]. - The weighted average return on net assets was 4.57%, down 6.01% from 10.58% in the previous year[23]. - The total assets at the end of the reporting period were RMB 1,616,759,929.25, a decrease of 0.74% from RMB 1,628,782,391.06 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were RMB 1,364,586,769.79, down 1.21% from RMB 1,381,254,751.49 at the end of the previous year[23]. Cash Flow and Investment - The net cash flow from operating activities was -RMB 61,793,890.39, a significant decrease of 1,106.97% compared to RMB 6,136,644.18 in the previous year[23]. - The company reported a net cash flow from investment activities of -¥76,646,731.28, which is a 67.89% increase in outflows compared to -¥45,651,919.97 last year, driven by ongoing investments in the health industry park project[60]. - The total amount of funds raised by the company is RMB 72,559.56 million, with RMB 11,326.24 million invested during the reporting period[72]. - The cumulative amount of raised funds invested to date is RMB 53,906.02 million, representing 74.3% of the total raised[72]. - The cash and cash equivalents at the end of the reporting period amount to RMB 1,371,049.26, restricted due to acceptance bill guarantees and electricity deposit guarantees[68]. Research and Development - The company has established multiple research platforms, including provincial high-tech enterprise research centers and post-doctoral workstations, to enhance its core competitiveness in the pharmaceutical sector[43]. - The company is actively involved in new product development, with several products like Bone Spur Capsules and Liver Su Capsules already listed and undergoing regulatory approvals[44]. - Research and development investment rose by 27.93% to ¥9,271,145.23, up from ¥7,246,990.93, reflecting a commitment to innovation[60]. - The company is focusing on research and development in antibiotic, detoxification, and gynecological drug areas, aligning with market demand[43]. Market and Sales Strategy - The company operates a dual sales model, with OTC drugs primarily sold through direct supply and prescription drugs mainly through distribution channels[39]. - The pharmaceutical manufacturing segment generated revenue of ¥244,435,693.30, reflecting a slight increase of 0.06%, while the pharmaceutical commercial segment saw a significant revenue increase of 40.42%, totaling ¥87,394,663.16[40]. - The company plans to launch two new products in Q3 2021, aiming to capture a 5% market share in the new segments[108]. - Future outlook includes an expected revenue growth of 20% for the full year 2021, driven by market expansion and new product launches[109]. Risks and Challenges - The company faces risks including policy risks, drug quality control risks, and management risks due to rapid expansion[4]. - Quality control risks are present due to the complexity of drug production, with measures in place to ensure compliance with safety and efficacy standards[84]. - Management risks are anticipated due to rapid expansion, prompting the company to enhance training and recruitment of management personnel[85]. Corporate Governance and Compliance - The company has committed to protecting the rights of small and medium shareholders and ensuring a fair operating environment for suppliers and customers[97]. - The company emphasizes compliance with labor laws and provides social insurance for employees, including basic medical, unemployment, and pension insurance[99]. - The company actively engages in social responsibility initiatives, including health consultations and charitable donations, especially during the COVID-19 pandemic[100]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[92]. - The company will publicly disclose the reasons for not implementing stabilization measures at the shareholders' meeting and in designated publications[117]. - The company will adhere to the principles of the stabilization plan, ensuring compliance with legal and regulatory requirements[113]. Future Outlook - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 25%[142]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence in the pharmaceutical sector[110]. - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels by the end of 2021[128].

Financial Performance - The company's revenue for Q1 2021 was ¥132,259,899.28, representing a 7.74% increase compared to ¥122,754,754.51 in the same period last year[7] - Net profit attributable to shareholders was ¥20,272,669.37, up 28.86% from ¥15,732,140.29 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥19,671,120.10, reflecting a 26.09% increase from ¥15,601,124.90 in the previous year[7] - Basic earnings per share decreased by 3.37% to ¥0.2520 from ¥0.2608 year-on-year[7] - Total operating revenue for Q1 2021 was CNY 132,259,899.28, an increase from CNY 122,754,754.51 in the previous period[53] - Net profit for Q1 2021 reached CNY 20,371,610.56, representing a 29.5% increase from CNY 15,732,140.29 in Q1 2020[55] - Operating profit for Q1 2021 was CNY 23,685,671.98, up 24.0% from CNY 19,036,151.28 in the previous year[55] Cash Flow and Liquidity - The net cash flow from operating activities was -¥45,004,162.70, a significant decline of 2937.93% compared to -¥1,481,406.73 in the same period last year[7] - Cash flow from operating activities for Q1 2021 was CNY 134,001,330.89, an increase from CNY 119,173,835.10 in the same period last year[62] - The company reported a total cash outflow of 182,501,552.16 CNY from operating activities, which is a 43% increase compared to the previous period[63] - The ending balance of cash and cash equivalents was 484,957,165.65 CNY, down from 593,975,811.41 CNY at the beginning of the period[64] - The company experienced a net decrease in cash and cash equivalents of 109,018,645.76 CNY during the period[64] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,612,680,869.75, a decrease of 0.99% from ¥1,628,782,391.06 at the end of the previous year[7] - Total liabilities decreased to CNY 170,676,977.62 from CNY 207,952,826.21 in the previous period[51] - Current liabilities were CNY 127,641,978.57, down from CNY 177,209,223.49 in the previous period[51] - Total current assets decreased to ¥945.20 million from ¥998.62 million, reflecting a decline of about 5.3%[45] - The total current liabilities increased from CNY 177,209,223.49 to CNY 213,650,314.37, indicating a rise in short-term financial obligations[73] Shareholder Information - The company reported a total of 15,486 common shareholders at the end of the reporting period[11] - The largest shareholder, Liu Zhongliang, holds 60.82% of the shares, totaling 48,921,389 shares[11] - The total equity attributable to shareholders reached CNY 1,456,966,924.27, compared to CNY 1,439,473,664.76 in the previous period[51] Operational Highlights - The company is executing its annual business plan smoothly, with all operations proceeding in an orderly manner[24] - The company faces policy risks due to ongoing national healthcare reforms, which could impact operations if not addressed timely[25] - The company has established a comprehensive quality management system to mitigate risks associated with product quality control[27] - The company is developing generic drug projects and secondary development of key products, which require lower investment and shorter R&D cycles[28] Research and Development - R&D expenses decreased by 30.66% to 4.09 million yuan, attributed to reduced external R&D costs[18] - Research and development expenses for Q1 2021 totaled CNY 4,091,733.61, a decrease of 30.6% from CNY 5,900,941.97 in Q1 2020[55] Investment and Capital Expenditure - The company approved an additional investment of ¥97.21 million in the pharmaceutical health industry park project, increasing the total planned investment to ¥358.62 million[36] - The company has a total of CNY 745,116,281.86 in capital reserves, indicating strong financial backing[71] Risk Management - Management risks are anticipated due to rapid expansion, prompting the company to enhance training for existing management personnel and recruit new staff[29] - The company has not reported any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[39] - There were no significant changes in the feasibility of investment projects during the reporting period[36]

Financial Performance - The company's operating revenue for 2020 was ¥622,766,990.78, a decrease of 2.97% compared to ¥641,800,892.91 in 2019[17]. - The net profit attributable to shareholders for 2020 was ¥135,815,760.84, representing an increase of 7.78% from ¥126,012,754.58 in 2019[17]. - The net cash flow from operating activities decreased by 62.03% to ¥42,812,190.40 in 2020, down from ¥112,762,180.44 in 2019[17]. - The total assets at the end of 2020 were ¥1,628,782,391.06, an increase of 85.96% from ¥875,868,201.72 at the end of 2019[17]. - The net assets attributable to shareholders increased by 165.71% to ¥1,381,254,751.49 at the end of 2020, compared to ¥519,843,367.06 at the end of 2019[17]. - The basic earnings per share for 2020 was ¥2.030, a decrease of 2.87% from ¥2.090 in 2019[17]. - The company reported a total of ¥26,442,631.68 in non-recurring gains and losses for 2020, compared to ¥17,027,436.39 in 2019[23]. - The total profit for 2020 was CNY 158,701,874.87, reflecting a year-on-year increase of 7.49%[66]. - The company achieved a net profit of CNY 300 million in 2020, which is an increase of 20% compared to the previous year[161]. Dividend Distribution - The company plans to distribute a cash dividend of 10 RMB per 10 shares to all shareholders, based on a total of 80,439,068 shares[4]. - The cash dividend for 2020 represents 59.23% of the net profit attributable to ordinary shareholders, which was 135,815,760.84 CNY[140]. - The cash dividend for 2020 is the first cash return to shareholders since the company's IPO[140]. - The remaining undistributed profits will be carried forward to the next year, with no stock dividends or capital reserve transfers planned[138]. - The cash dividend distribution plan is subject to approval at the 2020 annual general meeting[138]. Business Overview - The report covers the company's business overview and major financial indicators for the year 2020[12]. - The company’s main business includes the research, production, and sales of modern Chinese and Western medicines, with key products including Yinhuang Dripping Pills and Yimucao Soft Capsules[26]. - The company operates retail pharmacy chains primarily in Lishui and Hangzhou, along with traditional Chinese medicine clinics in both cities[37]. - The company has established multiple research platforms, including provincial-level high-tech enterprise R&D centers and expert workstations, to enhance its core competitiveness in the pharmaceutical field[39]. Market Expansion and Future Outlook - Future outlook remains positive, with a projected revenue growth of 10% for the next fiscal year, driven by market expansion and new product launches[52]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[52]. - Market expansion efforts include targeting tier-2 cities, with plans to open 20 additional stores in these regions[54]. - The company plans to launch three new products in the next quarter, focusing on chronic disease management and preventive care[53]. Research and Development - The company focuses on the R&D of new drugs in areas such as antibiotics, heat-clearing and detoxifying, and gynecology, emphasizing technology development and market demand[39]. - Research and development investment increased by 25%, totaling 100 million RMB, aimed at enhancing product efficacy and safety[53]. - The company plans to enhance its R&D efforts by constructing a new R&D center and upgrading advanced equipment, with a focus on secondary development of existing key products[117]. Risk Management - The company acknowledges potential risks including policy risks, drug quality control risks, and market competition risks, which are detailed in the report[4]. - The report emphasizes the importance of understanding the differences between plans, forecasts, and commitments, urging investors to maintain adequate risk awareness[4]. - The company anticipates management risks associated with rapid expansion, necessitating training and recruitment of management personnel[129]. Compliance and Governance - The company operates under the regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[9]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, including the chairman and accounting manager[3]. - The company has committed to fulfilling all promises made by shareholders and related parties during the reporting period[141]. Share Repurchase and Stock Price Stabilization - The company plans to repurchase shares to stabilize stock prices, ensuring that the repurchase results do not lead to a distribution of equity that does not meet market conditions[146]. - The total amount of funds used for share repurchase will not exceed 50% of the net profit attributable to the parent company for the previous fiscal year[149]. - The company will initiate a board meeting to discuss stock price stabilization plans within three trading days if the stock price conditions are met[147]. Corporate Social Responsibility - The company has made commitments regarding the repayment of social insurance and housing fund contributions for employees, ensuring no financial losses arise from such obligations[181]. - The company is committed to protecting the interests of investors, especially small and medium-sized investors, in case of any legal violations[169].